Press Release #2: Exciting Gene Therapy Progress and Upcoming International CTNNB1 Conference

We are thrilled to announce significant advancements in our ongoing research on CTNNB1, along with details of the upcoming 2nd International CTNNB1 Conference.

Breakthrough in Preclinical Tests and Collaboration with University of Oxford

Our dedicated research team has achieved a remarkable milestone in CTNNB1 gene therapy. Recent preclinical tests have shown promising results, with the expression of beta-catenin closely mirroring healthy levels. This significant development has been accomplished in less than three years, showcasing our team's dedication and expertise.

In an exciting collaboration, we are proud to work alongside Professor Laurent Servais from the University of Oxford, a distinguished figure known for his expertise in clinical trials for SMA, DMD, and Angelman syndrome. Our partnership aims to pave the way for an upcoming clinical trial, anticipated to commence between late 2024 and early 2025.

2nd International CTNNB1 Conference in Ljubljana, Slovenia

We are delighted to invite you to the 2nd International CTNNB1 Conference, set to take place at the Grand Plaza Hotel & Congress Centre in the picturesque city of Ljubljana, Slovenia. This conference is a golden opportunity for experts, researchers, families, and stakeholders to converge, share insights, and foster hope in the journey towards a cure.

Call for Participation and Support

As we progress towards our clinical trials, we are in need of four families to participate in a preliminary study in Belgium, in collaboration with Dr. Servais. The study involves testing a new device, ActiMyo, to gather valuable data for the upcoming trials. We warmly encourage interested families to reach out for this pivotal study.

Our research and trials heavily rely on the generosity of our supporters. We are in the midst of a fundraising drive to expand our production capabilities. Every contribution, no matter how small, is a step towards our ambitious goal of increasing production. We urge the community to join hands in this noble cause.

Looking Ahead with Optimism

The journey of the CTNNB1 research has been both challenging and rewarding. As we stand on the brink of potential groundbreaking advancements, we invite you to be a part of this exciting journey. Join us at the 2nd International CTNNB1 Conference to witness, engage, and contribute to this historic moment in medical research.

Together, we are making strides towards a brighter future for those affected by CTNNB1-related conditions. Your support, participation, and generosity are invaluable to our mission.

Save the Date: 2nd International CTNNB1 Conference, Ljubljana, Slovenia.

For more information and to contribute, please contact us at [email protected] or visit our website. Let's unite in knowledge, progress, and hope. Your involvement makes a world of difference.